Parexel Expands Market Access, Clinical Evidence Services

November 9, 2015

Applied Clinical Trials

Parexel announces PAREXEL® Access, a service that is directed toward clients’ market access and ongoing commercial success.

Parexel announces PAREXEL® Access, a service that is directed toward clients’ market access and ongoing commercial success. PAREXEL Access combines the expertise of HERON™ Commercialization, QSI’s pharmacovigilance, PAREXEL Medical Communications, and PAREXEL Peri-/Post-approval services, which focuses on clinical research and operations, market access consulting, medical communications, and pharmacovigilance to help companies identify, evaluate, generate and communicate the evidence of its product.

Read the full release.

Related Content:

News